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Abstract
HIV has become one of the most feared diseases in the world. It has claimed millions of
lives, especially in Sub-Saharan Africa. Although it is impossible to cure, studies have
shown that using antiretroviral therapy (ART) can greatly improve quality of life and
decrease viral load. There are four main classes of ART—NRTIs, NNRTIs, protease
inhibitors, and fusion inhibitors. Although access to ART is improving, it is vital that its
use is increased in Sub-Saharan Africa, where the prevalence can be as high as 33%.
This thesis explores the current need of ART in Sub-Saharan Africa, as well as
the existing coverage. In addition, it addresses the obstacles preventing ART distribution
and use—both provider and patient-related. Provider-related obstacles include limited
availability of drugs, total cost, lack of healthcare staff and facilities, lack of organization,
and government regulations. Patient-related obstacles include cost, transportation,
geographic proximity to healthcare facilities, side effects and hunger, pill burden,
hospital-related factors, cultural beliefs, social stigma, lack of adequate counseling, and
drug resistance. It is important to be proactive, assess ART delivery, consider suggestions
for improvement, and tackle the HIV epidemic.
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Antiretroviral Therapy: Use in Sub-Saharan Africa
and Common Obstacles Encountered
The epidemic of human immunodeficiency virus (HIV) has torn apart many
families and stolen many lives within the last 20 years. Every day, about 5700 people in
the world die from AIDS and 6800 people become newly infected with HIV.
Approximately two thirds of people living with HIV reside in Sub-Saharan Africa,
making it the most seriously affected region in the world (UNAIDS/WHO, 2007).
Providing treatment in this region and throughout the world is a major healthcare
concern. There are currently four classes of drugs that have been formulated to target this
virus. Even though none of these medications cure HIV, they have proved to drastically
decrease viral load and improve the patient’s quality of life. In order to provide
antiretroviral therapy in Sub-Saharan Africa, healthcare professionals first need to be
familiar with HIV itself and the drugs that are available to treat it. Secondly, it is also
important for them to assess the current need in their area and compare it with the percent
receiving antiretroviral therapy. Finally, since there are many obstacles in distributing
and maintaining treatment, it is imperative that they are identified and addressed so that
this devastating epidemic can be brought to an end.
Human Immunodeficiency Virus
There are two different types of human immunodeficiency virus—HIV-1 and
HIV-2. HIV-2 is found solely in West Africa, as opposed to HIV-1, which has
documented cases worldwide. The majority of research has been done on HIV-1 since it
is the more prevalent type of HIV. In order to produce medications to treat this
devastating disease, the structure of the virus had to be understood as well as its
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mechanism of infection. With this knowledge, particular drugs were devised to inhibit
specific steps of the process (Lehne, 2007).
Concerning its structure, the virus contains several main components: a core, a
protein capsid and a lipid envelope. The core consists of single-stranded RNA and
proteins (Lehne, 2007). See Figure 1.

Figure 1. Structure of HIV Viron (NIAID, 2004)
Viruses are not technically living organisms due to the fact that they rely on a host
to assist in replication. HIV can enter the body through a variety of means. The most
common modes of transmission include sexual intercourse, the use of contaminated
needles, vertical transmission from mother to child, and breastfeeding (Vella &
Palmisano, 2005). Regardless of how the virus is introduced to the body, HIV replicates
and spreads in the same manner. Its first task is to locate a CD4 cell—a type of helper T
lymphocyte. Once it finds one, glycoproteins (gp120 & gp41) on HIV’s envelope attach
to specific proteins on the CD4 cells’ membrane. The membranes fuse and HIV injects its
RNA into its new host (Lehne, 2007). An enzyme called reverse transcriptase transcribes
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the viral RNA into DNA. Then this DNA can be incorporated into the CD4 cell’s DNA.
Therefore, the virus’ genetic material is replicated along with the CD4 cell’s DNA. This
enables the virus to multiply itself. A daughter viron forms when the RNA and proteins
migrate toward the edge of the cell and bud off. Final maturation occurs when large
polyproteins in the viron are broken into smaller, functional proteins by an enzyme called
protease. If this step is not completed, the viron is not infectious (Lehne, 2007).
Once a person is infected with HIV, he or she may live up to 10 years without any
signs of the disease. Despite the slow emergence of symptoms, the virus is rapidly
replicating and destroying CD4 cells. In the initial phase on infection, there can be up to
10 million virons per milliliter of blood. At this point, the individual has not mounted an
immune response yet, allowing the virus to replicate unopposed. In addition, there is still
a high CD4 count, which gives the HIV many vulnerable targets. Once the body’s
immune system begins to attack, the number of virons per milliliter reduces to between
1,000 and 10,000. Yet, this is still an astronomical number (Lehne, 2007).
Drugs Available to Treat HIV
As the HIV epidemic spread globally, researchers recognized the immediate need
for medicine. By studying the mechanism of the virus described briefly above, four main
classes of medications were invented. These include NRTIs, NNRTIs, protease inhibitors,
and fusion inhibitors (see Table 1). The treatment of HIV is called ART (antiretroviral
therapy). It is generally recommended that patients are on regimens of three of four
drugs. Using only one or two drugs is not typically prescribed because the probably of
resistance is high. One possible exception is pregnant women (Lehne, 2007). Multiple
studies have been conducted in order to determine the most effective regimens. These
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have become known as HAART (Highly Active Antiretroviral Therapy) (Justesen,
2005).
Table 1. Drugs of Antiretroviral Therapy (Lehne, 2007)
NRTIs

Protease Inhibitors

Abacavir (Ziagen)
Didanosine (Videx)
Emitricitabine (Emtriva)
Lamivudine (Epivir)
Stavudine (Zerit)
Tenofovir (Viread)
Zalcitabine (Hivid)
Zidovudine (Retrovir)
Acabavir/lamivudine (Epzicom)
Acabavir/lamivudine/zidovudine (Trizivir)
Emtricitabine/tenofovir (Truvada)
Zidovudine/lamivudine (Combivir)

Amprenavir (Agenerase)
Atazanavir (Reyataz)
Fosamprenavir (Lexiva)
Indinavir (Crixivan)
Nelfinavir (Viracept)
Ritonavir (Norvir)
Saquinavir (Invirase or Fortovase)
Tipranavir (Aptivus)
Lopinavir/ritonavir (Kaletra)

NNRTIs
Delavirdine (Rescriptor)
Efavirenz (Sustiva)
Nevirapine (Viramune)

Fusion Inhibitors
Enfuvirtide (Fuzeon)

The goals of HAART include the following: to diminish the viral load as much as
possible, maximize the number of CD4 cells, restore and preserve immune function
(reducing the risk of opportunistic infections), improve quality of life, and decrease
mortality. The effectiveness of antiretroviral therapy has been very promising within the
last couple of years. A patient on HAART should have a sharp drop in HIV RNA by the
end of 8 weeks of therapy. In addition, HIV can often become undetectable (fewer than
50 HIV RNA copies per mL) after 4 to 6 months. Even if this is the case, patients must
continue following their drug regimen. Unfortunately, there is no complete cure for HIV
or AIDS due to the fact that some virons remain dormant in CD4 cells (Lehne, 2007).
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Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) were the first HIV
medications to be discovered. They have been considered the “backbone” of all
antiretroviral regimens. They are convenient pills and have few drug interactions. The
prototype of this class is zidovudine, which has been known to reach the CNS better than
any other ART drug. Collectively, NRTIs are effective medications as a result of their
structure—they are chemically similar to nucleosides (the building blocks of DNA). They
can act as competitive inhibitors of reverse transcriptase. During transcription, reverse
transcriptase uses the drug as a nucleoside, incorporating it into the DNA strand. This
prevents other nucleosides from binding, which in turn terminates transcription (Lehne,
2007 & Justesen, 2005).
Non-nucleoside Reverse Transcriptase Inhibitors
A second class of ART that also inhibits reverse transcriptase is called a nonnucleoside reverse transcriptase inhibitor (NRTI). Instead of acting like a nucleoside, it
binds to an active site on reverse transcriptase, directly inhibiting it. Currently, efavirenz
is the only NNRTI preferred for treating HIV. Typically, NNRTIs are given in
combination with NRTIs and are administered in pill form. There are a couple
disadvantages and limitations with the use of NNRTIs. First of all, resistance to this drug
occurs more frequently than with any of the other classes. This is due to the high rate of
mutation. It is estimated that 10 incorrect base pairs are incorporated into viral DNA
during every replication. Secondly, it is only used for HIV-1; it is ineffective in treating
HIV-2 (Lehne, 2007 & Justesen, 2005).
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Protease Inhibitors
Protease inhibitors (PIs) are known as the most effective antiretroviral drugs.
They are also given in pill form. When given in combination with NRTIs, the viral load is
often undetectable. Sometimes it will also be given with a second PI, which boosts its
effects. Concerning their mechanism of action, they inhibit the last step of viral
replication (when an enzyme called protease breaks large polyproteins into smaller,
functional proteins). If a patient is on a protease inhibitor, the drug binds to active sites
on protease which makes it inactive. This leaves the viron immature and unable to
become infectious. There are many positive aspects about using a PI—it is less selective
than some of the other drugs, treats both HIV-1 and HIV-2, and can be used to treat
children. Lopinavir can be used in infants as young as 6 months old and nelfinavir in
children at least two years old. Another valuable use for PIs is in some resistant cases.
Tipranavir/ritonavir (a combination drug) is flexible and is able to adapt the shape of HIV
as it mutates. Therefore, it can effectively halt viral replication in resistant cases. A
negative aspect of protease inhibitors is that it can cause multiple drug interactions by
increasing other drug levels (Lehne, 2007 & Justesen, 2005).
Fusion Inhibitors
The only fusion inhibitor is enfuvirtide, also known as T-20. Unlike all of the
other classes of antiretroviral drugs that work by inhibiting enzymes, this one actually
stops HIV from entering into the CD4 cells. It binds to gp41 on the virus, stiffening the
glycoprotein. Since it is no longer able to mold into other shapes, it is unable to fuse with
the CD4 cells’ membranes. This halts infection. The positive aspects of using a fusion
inhibitor is that it is often very effective, it can be useful for patients with a resistant
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strain of HIV, and it has few known drug interactions Unfortunately, this medication is
not as widely used because it is inconvenient and expensive. It takes 106 steps to make
this drug (in contrast to the 8-12 steps required for NRTIs, NNRTIs and PIs). Therefore,
the cost is high—approximately US$20,000 per year. In addition, fusion inhibitors are
inconvenient because they require two subcutaneous shots every day. It is also limited to
HIV-1 and children over age 6 (Lehne, 2007 & Justesen, 2005).
Preferred Regimen
The preferred HAART regimens are listed below in table 2 (Lehne, 2007).
Table 2. Preferred HAART Regimens (Lehne, 2007)
Regimen

Drugs of the Regimen

NNRTI based

Efavirenz + (lamivudine or emtricitabine) + (zidovudine or

(1 NNRTI + 2NRTIs)

tenofovir)

PI based

Lopinavir/ritonavir (Kaletra) + (lamivudine or emtricitabine) +

(1 PI + 2 NRTIs)

zidovudine

The Need for Antiretroviral Therapy in Sub-Saharan Africa
In order to provide HIV treatment, healthcare professionals need to assess the
need in their area and compare it to the percent of patients who are receiving ART. The
United Nations Programme of HIV/AIDS (UNAIDS) and the World Health Organization
(WHO) have compiled statistics to provide healthcare providers with this information.
The map in Figure 2 displays the prevalence of HIV/AIDS throughout the world.
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Figure 2. Prevalence of HIV/AIDS in 2006
(Retrieved from the WHO website: http://gamapserver.who.int/mapLibrary/Files/Maps/HIVPrevalence
Global2006.png).

Concerning total need, they estimated that there were 33.2 million people in the world
living with HIV in the year 2007. 22.5 million of these people (two thirds) were from
Sub-Saharan Africa. In addition, nearly 90% of the children in the world infected with
HIV live in this region. Concerning mortality, 2.1 million of people in the world died of
AIDS in 2007. 1.6 million of these people were Sub-Saharan Africans. This means that
three quarters of all deaths from AIDS were in this region. In fact, AIDS is the leading
cause of death in Sub-Saharan Africa. (UNAIDS/WHO, 2007). HIV/AIDS has drastically
reduced the life expectancy in some of these countries. For instance, in South Africa, the
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male life expectancy dropped from 61.5 in 1994 to 49.2 in 2000. This decline was mainly
due to the increasing prevalence of HIV/AIDS cases (Kapp, 2004).
Approximately 5% of people in Sub-Saharan Africa are infected with HIV, which
is drastically higher than the rest of the world (<1%). However, the prevalence varies
greatly county to country (see table 3) (UNAIDS/WHO, 2007).
Table 3. Prevalence of HIV Reported in the 2006 WHO Report on the Global AIDS
Epidemic (UNAIDS/WHO, 2007)
Country
% of
Population
Benin
1.8
Botswana
24.1
Burkina Faso
2.0
Burundi
3.3
Cameroon
5.4
Central African Republic
10.7
Chad
3.5
Cote d’lvoire
7.1
Equatorial Guinea 3.2

Country
Population
Ethiopia
Ghana
Guinea
Kenya
Lesotho
Malawi
Mali
Niger
Rwanda

% of
1.4
2.3
1.5
6.1
23.2
14.1
1.7
1.1
3.1

Country
% of
Population
Senegal
0.9
Sierra Leone
1.6
South Africa
18.8
Swaziland
33.4
Uganda
6.7
Tanzania
6.5
Zambia
Zimbabwe

17.0
20.1

The majority of the countries in Sub-Saharan Africa that have a high prevalence of HIV
are in located in southern Africa. Countries of particular concern include Swaziland (who
has a prevalence of 33.4%), Botswana (24.1%), Lesotho (23.2%), Zimbabwe (20.1%),
South Africa (18.8%), and Zambia (17%). The prevalence of HIV in the countries of East
Africa have been relatively stable, and are even beginning to decline. This is the same for
many of the countries in West and Central Africa (UNAIDS/WHO, 2007). Organizations
such as the WHO and UNAIDS use this information to narrow in on the areas with the
greatest need.

Antiretroviral Therapy 13
Use of ART in Sub-Saharan Africa
As a result of increased awareness and funding, the distribution of ART in SubSaharan Africa has been improving substantially. This has greatly improved the clinical
outcome of the disease and reduced the death rate. Although the patients will have to
remain on ART for the rest of their lives, their ability to live and function in society is
greatly improved. Many patients make a complete turnaround and no longer display
outward signs and symptoms of HIV. In addition, many patients’ viral loads diminish to
undetectable levels. However, one of the major problems in Sub-Saharan Africa is that
the majority of people are not tested for the disease. In fact, less than 10% of HIVinfected people in this region know that they are HIV positive. Most people with HIV are
not tested for it until they are admitted into the hospital for opportunistic infections
(Colebunders, Ronald, Katabira, & Sande, 2005).
Still, as education and prevention are promoted, more and more patients are being
tested for HIV. Once HIV is diagnosed and the patient’s disease is staged, the physician
determines the patient’s need for antiretroviral therapy. The World Health Organization
(WHO) recommends that in resource-limited settings, ART is given to patients who fall
in one of these categories:
•

Stage I or II HIV with a CD4 cell count below 200/mm3

•

Stage III HIV with a CD4 cell count below 350/mm3

•

Stage IV HIV

These recommendations are in place to help guide physicians in providing ART in areas
where there are not enough resources and for every HIV patient to receive therapy
(WHO, 2003).
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The recommended regimens for Africa usually include one NNRTI and two NRTIs.
These drugs are cheaper and more accessible in developing countries (Colebunders,
Ronald, Katabira, & Sande, 2005). The WHO recommends using one of the following
regimens:
•

stavudine + lamivudine + neverapine

•

zidovudine + lamivudine + neverapine

•

stavudine + lamivudine + efavirenz

•

zidovudine + lamivudine + efavirenz (WHO, 2003)
A study in Botswana collected information and compiled statistics about the use

of the different types of ART. Of ART receivers, 31% were taking a combination of at
least three drugs (18% on PI regimen plus 13% on NNRTI regimen). From the rest of the
patients, 52% were only able to afford one drug or a combination of two drugs. The most
common class of drug given by itself was an NRTI. The remaining regimens (17%) were
unclear (Weiser, Wolfe, Bangsberg, Thior, Gilbert, Makhema, 2003). Studies such as this
one are important because they provide data that can be further researched to determine
effectiveness of drug regimens.
It is very important that HIV drug coverage is analyzed and evaluated on an
annual basis. The number of HIV-infected people living in Sub-Saharan Africa needs to
be compared to the number of patients that are receiving ART. This will provide data
regarding the current state of ART distribution. Therefore it helps to ensure that
distribution is increasing and maintenance is improving. Figure 3 shows the coverage in
Sub-Saharan Africa in the year 2006.
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Figure 3. ART Coverage in Sub-Saharan Africa in 2006
(Retrieved from the WHO website: http://gamapserver.who.int/mapLibrary/Files/Maps/Africa_ARV
Coverage_A4_100407.png).

In 2003, the WHO declared a goal of reaching 3 million HIV patients by the year
2005. It was called the “3 by 5” initiative. Although, the goal was not met, there was a
drastic improvement in the distribution of antiretroviral therapy. In 2003, only about
400,000 HIV patients from low or middle-income countries were receiving ART. By the
year 2005, this increased to 1.3 million people. In Sub-Saharan Africa, the number of
patients on ART increased drastically from 100,000 to 810,000 between 2003 and 2005
(see table 4) (WHO/UNAIDS, 2006). In the year 2007 1.3 million people in this region
were on ART. This is approximately 28% of their HIV population. Currently, the WHO
and UNAIDS are pushing towards universal access by 2010. (WHO/UNAIDS, 2007).
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Table 4. Estimated Distribution of ART in Sub-Saharan Africa for 2005
Country

HIV patients
in need of ART
SOUTHERN AFRICA
Angola
52,000
Botswana
84,000
Lesotho
58,000
Madagascar
20,000
Malawi
169,000
Mauritius
--Mozambique
216,000
Namibia
41,000
South Africa
983,000
Swaziland
42,000
Zambia
183,000
Zimbabwe
321,000
EAST AFRICA
Burundi
46,000
Eritrea
11,000
Ethiopia
278,000
Kenya
273,000
Rwanda
49,000
Somalia
6,000
Uganda
148,000
United Republic
315,000
of Tanzania
WEST AFRICA
Benin
14,000
Burkina Faso
34,000
Cameroon
108,000
Cote d’Ivoire
111,000
Gambia
1,500
Ghana
61,000
Guinea
23,000
Liberia
15,000
Mali
22,000
Niger
12,000
Nigeria
636,000
Senegal
9,000
Sierra Leone
9,600
Togo
25,000
CENTRAL AFRICA
Central African
49,000
Republic

HIV patients who
received ART

ART
coverage

2500-3500
67,000-77,000
7,500-9,000
<200
31,000-35,000
<200
19,000-21,000
27,000-31,000
178,000-235,000
12,000-14,000
45,000-52,000
22,000-27,000

6%
85%
14%
0%
20%
--9%
71%
21%
31%
27%
8%

6,000-7,000
<1000
19,000-22,000
60,000-72,000
18,000-20,000
--71,000-79,000
20,000-23,000

14%
5%
7%
24%
39%
1%
51%
7%

3,500-6,000
7,500-9,000
21,000-26,000
18,000-19,000
<200
4,000-5,000
2,000-2,500
<500
5,500-9,000
<1,000
37,000-45,000
3,000-5,500
<500
5,000-8,000

33%
24%
22%
17%
10%
7%
9%
3%
32%
5%
7%
47%
2%
27%

1,500-2,000

3%
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Chad
Democratic Republic of
the Congo

38,000
209,000

5,000-8,000
7,000-8,500

17%
4%

(WHO/UNAIDS, 2006).
Obstacles for Providing Treatment
In order to effectively treat HIV patients in Sub-Saharan Africa, it is important to
tackle the common obstacles to providing ART. There are two main types of obstacles:
provider-related obstacles and patient-related obstacles. Provider-related obstacles
include limited availability of drugs, total cost, lack of healthcare staff/heavy workloads,
lack of healthcare facilities, lack of organization, and government regulations. Patientrelated obstacles are typically related to adherence to the drug regimen. They can include
cost, transportation, geographic proximity to healthcare facilities, side effects and hunger,
pill burden, hospital-related factors, cultural beliefs, social stigma, lack of adequate
counseling, and lastly, drug resistance. Addressing these obstacles will help to provide
successful treatment to the maximum number of patients.
In order to supplement my research, I attempted to administer a survey (see
Appendix A) to healthcare providers in Africa. Unfortunately the response was poor. I
sent ten surveys to healthcare providers within a missions organization; I only received
one survey back. Despite the fact that this eliminates my ability to compare obstacles
between different countries, it did provide specific information on a hospital in Benin.
The government in Benin had begun to provide ART to this hospital in 2005; since then,
57 patients had been treated. Although they had access to NNRTIs, NRTIs and protease
inhibitors, their most common regimen was a NNRTI plus a NRTI. The obstacles
encountered in this hospital will be provided throughout the remainder of this thesis in
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conjunction with a review of existing studies.
Provider-Related Obstacles
Limited Availability of Drugs
As mentioned above (see Table 4), there are more HIV patients than the current
resources, drugs and healthcare facilities can supply. Only a limited number of patients
can be treated. This is one of the obstacles in providing antiretroviral therapy. In the
hospital in Benin that participated in my survey, approximately 80% of people seeking
HIV treatment were able to receive it through the hospital. This percent does not include
people with HIV who do not seek treatment. The reason why 100% of HIV patients were
not able to receive treatment is because the supplies and medications were limited. It is
also important to note that if patients become resistant, there is an even lower chance that
the second-line drugs will be available for them. Many of these patients will progress
quickly in the disease due to a lack of effective treatment.
High Cost
Since finances are an obvious limitation to providing drug therapy in resourcepoor settings, multiple organizations have published an estimate of the total cost.
Gutierrez, et. all complied information on what it would cost to see “3 by 5” come to
completion. They calculated the costs for the 34 countries that made up 90% of the
overall need. The estimate that they arrived at was a range from $5.1 billion to $5.9
billion. This was just to include the money that would be spent between 2003 and 2005.
They also included a chart of the distribution of this money: 43% for ART, 17.8% for
treating opportunistic infections, 12.2% for support costs (training health personnel,
supervision, etc), 10.1% for universal precautions, 9.1% for palliative care, 3.9% for
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program costs, 1.8% for opportunistic infection prophylaxis, 1.4% for ART monitoring
and laboratory costs, and 0.6% for testing and counseling. Concerning the costs of ART
in resource poor settings, first line therapy ranged from US$140 to US$304 per patient
per year. Second line therapy ranged from US$510 to US$1108. The costs then increased
even more for patients who were also diagnosed with TB or were pregnant (Gutierrez,
Johns, Adam, Bertozzi, Edejer, Greener, et al., 2004).
An even higher estimate has been released by the World Health Organization.
They estimated that for the year 2007, it would cost approximately $18.1 billion to treat
HIV globally. However, it was estimated that only about $10 billion dollars would be
available. The budget for the World Health Organization’s HIV/AIDS work has also been
short. From their needed $281 million, they were $120 million short. Therefore, their
research and impact was limited as well (WHO, 2006).
Concerning the current source of the needed money, many governments,
organizations, and outside donors contribute to the funding. The WHO estimated that in
the year 2006, about $8.9 billion came from existing pledges and commitments, and $2.8
billion came from domestic sources. In some middle- and upper-income countries, the
government covers 80-95% of HIV costs through public health programs and social
security. Financial support is crucial for some low- to middle- income countries.
However, even after combining the government’s own funding and outside funding, only
about 25-50% of the costs are typically covered. The rest has to be covered by the
patients or their families (WHO, 2006). This shows how finances are one of the main
barriers to reaching universal access to ART.
One way that the obstacle of cost can be addressed is to raise awareness. This can
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be done through a variety of means such as publications to the general public, news
reports on television, and using influential people as spokespersons. Both the cost of
providing ART and the current funding available need to be announced. It is also
important that funding is coordinated well. There are currently many programs and
organizations raising money for the HIV/AIDS crisis. They need to be overseen and
organized so that the resources are mobilized to where the need is.
Lack of Healthcare Facilities and Skilled Healthcare Workers
In order to effectively provide antiretroviral therapy, there must be a large base of
healthcare facilities and workers that are willing to participate. Healthcare providers are
the connection between the public and current medicine and technology. Unfortunately,
there is a lack of healthcare providers in Sub-Saharan Africa. This results in understaffing
of hospitals and clinics. In addition, since there are not sufficient numbers of healthcare
workers, new hospitals and clinics cannot be started. As a result, there are many people in
rural villages and towns that cannot receive medical care because there is not a healthcare
facility close enough to their home. In order to increase the number of healthcare
facilities dispersed in low-income countries, money must be raised and workers must be
recruited.
Compared to the rest of the world, Sub-Saharan Africa is lagging behind in their
workforce. Even though Africa has 14% of the world’s population and 25% of the
disease burden, they only have 1.3% of the health workers. On average, there are 0.8
health workers per 1000 people. The world’s average is more than quadruple this statistic
(4.2 per 1000 people). The WHO regional director for Africa stated that “Africa is
literally engaged in a war against diseases and health challenges of all descriptions—old,
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neglected, emerging, and re-emerging. This war cannot be fought without soldiers!”
(Sambo, 2007, p. 5).
There are multiple reasons why the health workforce is struggling. First of all, the
human resource departments in countries of Sub-Saharan Africa are lacking in structure
and organization. They often lack policies, are poor at planning, and have weak
management. In addition, they usually have inadequate incentive systems. It is a struggle
for these departments to recruit and retain workers for the healthcare field (LusambaDikassa, 2007).
Secondly, they often do not have the resources to adequately train and pay health
workers. Healthcare providers in Sub-Saharan Africa have very low salaries compared to
those in other countries. Therefore, recruiting for this region is difficult. Not only are
there insufficient funds for paying workers, but there are also not enough funds to cover
the cost of training. This can jeopardize the quality of training. The easiest place to train
healthcare workers is in the hospitals. Unfortunately, healthcare students who only
receive training in hospitals do not learn much about disease prevention and health
promotion. Instead, all of their training is based upon diagnoses and treatment. Therefore,
there is often a lack of holistic care. This affects the healthcare workers’ ability to educate
patients about HIV prevention. With more investment in healthcare training, institutions
could be evaluated and improved (Lusamba-Dikassa, 2007).
Thirdly, it is hard to recruit people to the health field, and even harder to keep
them there. Since there are few healthcare providers, the workload is high, especially in
the hospitals. This puts a large burden on the staff because they must provide care for so
many patients that they become overworked. A study in Tanzania showed that 82% of
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healthcare workers in Tanzania felt like they were overworked (Hardon, Akurut, Comoro,
Ekelzie, Irunde, Gerrits, et al., 2007). Being a healthcare professional can be very
frustrating and stressful. The combination of physical, emotional and mental stress often
leads to fatigue and burn-out. Therefore, this makes medical professions less attractive. In
Sub-Saharan Africa this leads to a high migration rate. Many healthcare workers leave
this region to work in countries where there is a better established healthcare system. This
is often attractive because workload is usually less, pay is better, and there are more
benefits and incentives (Marchal, De Brouwere, Kegels, 2005). Rates of migration in
African countries can be as high as 60% (Lusamba-Dikassa, 2007). According to the
South African Medical Association, more than 4000 doctors left the public health system
between 2000 and 2004. They either went abroad or started a private practice. This
roughly equaled the number of doctors trained within that time (Kapp, 2004).
Finally, HIV has a direct effect on the health workforce. Besides claiming the
lives of many healthcare workers, it also affects the morale and attitude of current
healthcare workers. The percent of HIV positive patients in the hospitals is on the rise,
which makes it worse. Currently about 46% of patients admitted into hospitals in South
Africa are HIV positive. Research has shown that AIDS patients stay almost twice as
long as patients without AIDS. In one study, AIDS patients stayed in the hospital an
average of 13.7 days. Non-AIDS patients were admitted in hospital for an average of 8.2
days. Therefore, this shows that this disease dramatically increases the need for medical
care. This leads to a high workload, stress, and fatigue. In addition, most patients with
HIV/AIDS are brought to the hospital in advanced stages of the disease. High death rates
among these patients lead to a sense of helplessness among healthcare workers (Marchal,
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De Brouwere, Kegels, 2005).
Fear of being exposed to HIV is an additional reason why it is hard to recruit and
maintain healthcare workers. Even though the actual risk of HIV transmission after
percutaneous exposure is only about 0.3%, the perceived risk is much higher. Often there
are inadequate supplies (such as gloves, gowns and disinfectant) for healthcare providers
to use to protect themselves. This instills fear in current healthcare workers, which then
affects the quality of care that HIV patients receive. It also deters potential healthcare
workers (Marchal, De Brouwere, Kegels, 2005).
Even if health workers do maintain their positions, the heavy workload and high
stress effects the care that they are able to give to their patients. The morale of current
health workers is often very low and it is hard to provide motivation. As a result, patients
often do not receive quality care. Quality care is no longer amongst the healthcare
workers’ main concerns. This is especially true for patients with HIV who are sometimes
neglected as a result of the healthcare worker’s fear of exposure. The low morale also
leads to a high rate of absenteeism (Marchal, De Brouwere, Kegels, 2005).
In order to improve morale and patient care, it is imperative that the shortage of
healthcare providers is addressed. Steps need to be taken to decrease the workload,
reduce the risk of exposure (and the fear associated with it), and reduce the rate of
migration of healthcare workers. In order to decrease the risk of exposure, universal
precautions need to be maintained on a stricter level. Facilities need to make it a priority
to provide all their staff with gloves, gowns, and goggles and to provide a safe way to
dispose of used needles and contaminated items. It is also important to adopt safer
nursing and medical techniques according to current research. Finally, post-exposure
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prophylaxis should be provided to healthcare workers free of charge (Marchal, De
Brouwere, Kegels, 2005). Adhering to these practices will help provide safety as well as
reduce fear. An additional way to reduce fear among healthcare workers is to provide
training about safe techniques as well as additional education about HIV. Since the
perceived risk is often much higher than actual risk, more education would help to reduce
the fear associated with exposure to HIV.
It is vital that these people work in the areas of greatest need. One way to improve
the retention of healthcare workers in smaller rural towns and villages is to recruit people
who live in particular towns or villages that are in need. These people can be trained in
larger cities and then return to their original home. Since they would have family and
friends in this area, it would be more likely that they would stay. Due to the fact that most
people in these rural areas would not be able to afford medical training, funds need to be
raised to provide scholarships and grants for their training.
It is also important that additional incentives are provided so that the medical field
in Sub-Saharan Africa becomes more attractive to healthcare workers. This will reduce
the rate of migration of healthcare workers out of Africa. One possible incentive is to
provide medical or nursing education at a reduced cost if students agree to work a certain
number of years in a particular location that needs healthcare workers.
In order to address the large workload, additional people need to be recruited to
join the medical field. For this come to fruition, effort needs to be put into the human
resource departments. Three of the main goals that HR departments should strive for are
improved planning and formation of policies, enhanced management, and better training
of staff. It is essential that progress is monitored and evaluated. Countries need to help
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human resource departments achieve these by allocating money, showing their political
commitment, and helping to raise awareness. Not only does each individual country need
to take leadership over the issue, but they need to be willing work collectively with other
countries and global organizations to discuss the most effective ways of enhancing
human resource departments (Lusamba-Dikassa, 2007).
Lack of Organization
Weiser said in his research study that it is important to “strengthen the health
infrastructures for delivering care” (Weiser, et al., 2003). In resource-poor countries
there is usually poor organization within the health field. As opposed to more developed
countries such as the United States, countries in Sub-Saharan Africa do not have very
well designed healthcare systems. Many do not have well planned programs, policies,
and procedures. Countries usually have to rely on plans and procedures suggested by
international organizations. They need to take it a step further by researching and
determining what works best for their country. Then they need to outline and organize
this information and amend policies and procedures as needed.
Poor organization often leads to poor communication. This has been an additional
challenge in Sub-Saharan Africa. If communication between the different healthcare
levels is lacking, reporting becomes more challenging. Therefore, it is difficult to put
together databases and study the epidemiology. In addition, also makes it difficult to
evaluate performance. Therefore, there is often a lack of accountability.
I have come across poor reporting and participation in research through my own
data collection. As stated above, I sent out 10 surveys regarding ART use and common
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obstacles encountered to healthcare professionals in different African countries. The
response was very poor; only one survey was returned.
Government Regulations Regarding ART
The extent of government involvement in HIV treatment varies greatly from
country to country. Government regulations can sometimes become obstacles to
healthcare providers. For instance, in Benin, the government selects which hospitals that
they will supply ART for. The remaining hospitals are unable to provide treatment for
their HIV patients. The selected hospitals have rules that they are supposed to follow,
regardless of if they are feasible or not. The nurse who completed my survey in Benin
said the following:
They have certain rules for following up with labtests, which I cannot always do,
since in our lab we cannot do the tests and they don't supply us with any money
for travelling elsewhere. (CD 4 and viral charge). There is also a whole pile of
paperwork to be done each month.
It was also mentioned that the government comes to check on their stock on a regular
basis. However, they have run out on several occasions. Even though governement
resources are necessary for HIV treatment, it is important to evaluate the government’s
regulations. It is important for them to address impractical or outdated regulations and
procedures.
Patient-Related Obstacles
Regardless of how efficient a country is at distributing ART, many patients face
multiple obstacles of their own, which drastically affects HIV treatment. According to a
study by Mshana, et al. in Tanzania, the top three areas of concern by potential ART

Antiretroviral Therapy 27
recipients were “financial constraints, reaching the regional hospital and sustaining
treatment” (Mshana, Wamoyi, Busza, Zaba, Changalucha, Kaluvya, et al., 2006). Each of
these factors affect how well the patients are able to adhere to their drug regimens.
Patient Adherence to Drug Regimen
Consistent adherence to the drug regimen is a vital factor in treating HIV/AIDS.
Optimal adherence is greater than 95%. This means that a patient can only miss one dose
in 10 days if he or she is on a twice-a-day regimen (Weiser, et al., 2003). If adherence is
poor (<80%), the drugs are not maintained at high enough concentrations to stop HIV
replication. This leads to detectable viremia, poor treatment outcomes, and even drug
resistance. A study of 45 HIV-infected patients determined that 87% of patients with less
than 80% adherence went into virologic failure (Chesney, 2000). Even nonadherence for
as short of a time as a week can result in rapid rebound of the virus (Weiser, et al., 2003).
There have been multiple studies that investigated adherence rates of countries in
Sub-Saharan Africa. A study conducted by Hardon, et al. in Botswana, Tanzania, and
Uganda in 2007 estimated that 77% of African patients adhere to the drug regimen
(Hardon, et al., 2007). However, according to a study by Weiser, et al., the levels of
adherence in Boswana were significantly lower. Using questionnaires and interviews they
collected data from 109 HIV patients and 60 healthcare providers in Botswana.
According to patients’ self-report, 54% of patients were adherent, 17% were nonadherent and 29% had gaps in treatment. Healthcare providers estimated that 56% of their
patients were adherent and 44% were non-adherent (Weiser, et al., 2003).
In developed countries such as the United States, poor adherence usually stems
from substance abuse, dietary restrictions, the “pill burden,” and side effects. However,
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research has shown that economic factors predominate poor adherence in resource-poor
settings (Chesney, 2000). It is actually rare that lack of motivation leads to poor
adherence. In fact, studies show that Africans are actually highly motivated to take their
medications as prescribed. However, there are many other constraints that limit their
ability to do so (Hardon, et al., 2007).
Many of the barriers to ART adherence were documented the study mentioned
above by Weiser, et al. They chose Botswana to collect their research because of the
high prevalence of HIV—the highest in the world. In fact, 60% of their hospital beds are
occupied by AIDS patients (Weiser, et al., 2003). The top reasons they listed for nonadherence are included in Table 5.
Table 5. Reasons Stated by Patients for Non-adherence (Weiser, et al., 2003)
Reason
Finances
Forgetting
Ran out of medicine
Travel
Side effects
Too busy
Doctor’s orders
Distance from clinic

Percent of
Patients
48%
29%
17%
13%
12%
12%
8%
5%

Reason
Hard to follow instructions
Too sick
Misunderstanding doctor
Pharmacy closed
Stigma
Alcohol
Felt better
Stresses at home/work

Percent of
Patients
5%
4%
3%
3%
3%
1%
1%
1%

It is also interesting to note that gaps in treatment were more common than day-to-day
non-adherence. This shows that patients are motivated to take their medication on a
regular basis. It is more common that barriers (such as cost or transportation) prevent
them from receiving their next supply of medication (Weiser, et al., 2003).
Concerning the adherence of HIV patients in Benin, the nurse who filled out my
survey stated the following:
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Most people are very keen to start treatment when they are very sick, but we have
seen some non-adherence by some of them when they were better. We have
decided not to put people on treatment anymore, unless we know where they live
and they have to sign an agreement before we start treatment with one other
member of their family or a friend present. This makes it easier to check up on
them when they don't show up for appointments.
Poor adherence in this hospital in Benin predominantly stemmed from the following
obstacles: lack of funds, geographic proximity to healthcare facility, and social/cultural
issues. Since they had only been distributing ART for two years, there was little data
about resistance. In addition, they had no way to test for resistance.
Although the major obstacles to optimal adherence will vary from country to
country, it is still important to analyze each one. The remainder of this thesis will provide
current research about the following obstacles: cost, transportation, proximity to
healthcare facilities, side effects and hunger, hospital-related factors, cultural beliefs,
social stigma, pill burden, lack of adequate counseling, and lastly, drug resistance.
Cost
The most widely mentioned barrier is cost. Many people with HIV will not seek
out treatment at all because they assume it will be too expensive. Even if they do seek out
treatment, many patients in rural towns and villages of Sub-Saharan Africa are unable to
pay. A patient interviewed in Mshana’s study said the following: “If you go to Bugando
without money, they will completely not care about you…there are good services if you
have money, but if you don’t have money, the services are not good” (Mshana, et al.,
2006, p. 653).
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As a result of the increasing awareness regarding HIV/AIDS in Sub-Saharan
Africa, funding is being increased to assist patients paying for ART. In fact, many
governments and organizations are beginning to provide ART free of charge. However,
this is not the case in all areas. In 2003, when Weiser et al. completed their study in
Botswana, patients were only receiving about one third of the cost of optimal ART.
Medical aid programs supplied up to 1,000 pula each month. However, the cost of a 3drug regimen ranged from 2,000 to 4,000 pula per month. If patients were able to afford
therapy at all, many of them had to resort to sub-optimal therapy, which was usually a
regimen of only one or two drugs. It was estimated that if cost was eliminated as an
obstacle for the patients in this study, good adherence would increase from 54-56% to
74% of the patients (Weiser, et al., 2003).
Even if the government or a nonprofit organization pays for the cost of ART,
there are still additional expenses that make it difficult for patients to afford their HIV
treatment. Many clinics and hospitals charge a registration fee or visit fees each time they
come to pick up the medication. In addition, often there are laboratory fees. These can be
difficult for patients with low incomes to pay. For instance, in one of the facilities in
Tanzania that participated in Hardon’s study, there was a visit fee up to US$3 and a
US$15 lab fee (Hardon, et al., 2007). However, the average daily wage in this country is
only about US$1.40 per day (Wikipedia, 2007 & Currency Converter, 2007). This would
cost approximately 13 days wages! In addition, these patients often lose an entire day’s
wages on the day that they visit the clinic or hospital (Hardon, et al., 2007).
Even if patients have enough money to cover these expenses, they may choose not
to continue with their drug regimen because they have other unrelated expenses that they
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would not be able to cover. It is important that these patients have enough remaining
money to care for their families—providing them with food, clothing and shelter. These
obligations are of more importance to them than their HIV treatment (Weiser, et al.,
2003). It is important that additional funds are raised to help patients pay for some of
these additional expenses. This will improve patient adherence overall. One way to do
this on an individual basis is through sponsorship programs. Families throughout the
world can sponsor an HIV patient, supplying extra money so that the patient can pay for
transportation, hospital fees, food, and additional costs.
Transportation
Transportation costs can also be a burden on patients. Some patients fail to make
it to follow-up visits where they would have received a refill on their medication. Most
Africans do not own a vehicle, therefore they must pay for a bus or taxi. For long
distances in Uganda, transportation can cost 30,000 shillings (US$17) round trip (Hardon,
et al., 2007). The average Ugandan only makes 42,000 shillings (US$24) per month
(Stoker, 2005). Therefore, this is huge cost! In addition to the cost of transportation, the
inconsistency and unreliability of transportation can make patients late. This means that
they may run out of pills before they are able to get back to the clinic or hospital. Overall,
cost and transportation are two of the main causes of sub-optimal adherence (Hardon, et
al., 2007).
If it is possible to raise additional funds, some of the money raised can be used to
help patients reach the healthcare facilities. However, since money is also one of the
largest obstacles this will probably not be an option for most countries. Another idea is to
buy a large van or other vehicle to pick up patients and provide transportation for follow-
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up visits. This will work best in towns where there is a large need and the distance
between patients’ homes is not very far.
Geographic Proximity to Treatment Facility
Another hindrance for people who need ART is that there is often not a healthcare
facility close enough for them to go to. As discussed above, this problem stems from the
fact that most countries are lacking in resources and in their number of healthcare
professionals. Some patients from Weiser et al.’s study said that they had to travel 8001000 km in order to reach the clinic or hospital. It was very difficult for them to do this
on a monthly basis (Weiser, et al., 2003). Even if there are closer hospitals and clinics,
many do not have the ability to test and treat HIV. There are many villages dispersed
throughout the Africa countries. Many are 100 km or more from cities where ART is
provided. Therefore, even if an HIV patient can make it to a healthcare facility once, it
will be difficult for him or her to go for follow-up visits every month to pick of more
medication. This leads to poor adherence. It is important that countries as a whole assess
their need for additional healthcare facilities based upon the need in various locations.
(Hardon, et al., 2007).
Side Effects and Hunger
Sometimes side effects that the patients experience can lead to poor adherence to
the drug regimen. Usually the side effects dissipate with time; however, some patients do
not know this. The most common side effects include headache, nausea, vomiting,
diarrhea, increased heart rate, rash, and swollen legs. If the effects are bad enough, some
patients will begin skipping doses, or quit altogether. Some patients will only take their
pill once a day instead of twice a day in order to alleviate some of the symptoms. In
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addition, sometimes the symptoms (such as sweating) are embarrassing, so patients will
not want to take the medication when they are out in public. This is another reason why
some patients skip doses (Hardon, et al., 2007).
Nearly every patient will experience side effects; however, they will be more
extreme in some patients than in others. Healthcare providers need to monitor their
patients for side effects. The patients who experience very mild side effects may be able
to live with the side effects. However, for the patients with severe side effects, healthcare
providers should look into other regimens. Adherence will improve if the symptoms with
the new regimen are less severe. It is also important that healthcare providers inform their
patients that some side effects will gradually dissipate over time. This will encourage
patients to remain adherent at the beginning of their regimens. If major side effects do not
wear off, they should notify their healthcare provider so that other regimens can be
explored.
Many patients on ART also complain of hunger during the initial stages of
treatment. As the body is regaining its weight and strength, it requires extra food
(Hardon, et al., 2007). It is also recommended that these patients eat a well-balanced
meal, which usually means they have to buy more expensive food. Patients in rural towns
and villages do not have the resources to buy supplemental food, or an increased quantity
of food. Often they will have a limited food supply at home and are unable to satisfy their
appetites. The hunger can become so bad that patients don’t want to take their
medication. A male participant in Mshana’s study can be quoted as follows: “you take
those medicines, they can overpower you, so you find it is just better to leave them, due
to lack of that food you need” (Mshana, et al., 2006, p. 653). This demonstrates how
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hunger can affect adherence to the drug regimen. Some healthcare facilities try to meet
this need by supplying their patients with supplemental nutrient and protein-rich flour and
foods.
Pill Burden
Some patients may get tired of going to the hospital and taking pills on a regular
basis. They may decide to take a break from it all. A Tanzanian who was interviewed
commented on the discouragement some HIV patients on ART experience: “…one who
can take them after some time gives up hope, [saying], ‘I have been taking these drugs for
many days now and I think it is enough…if I am to be cured I will be cured and if not,
then I don’t care even if I die, let me stop taking those drugs’” (Mshana, et al., 2006, p.
653). In addition, this is especially common in patients who are “feeling better.” They
may not see a need to continue their medication (Mshana, et al., 2006). Education is
needed in this situation.
Hospital-Related Factors
Sometimes patients are unwilling to begin or continue ART because they do not
trust hospitals. They might be hesitant to go to hospitals because of the hospital’s
reputation or because they have had a bad experience there in the past. For instance,
information gained through interviews in one study revealed that some staff at medical
facilities would demand bribes for access to healthcare. This deterred patients from
returning (Mshana, et al., 2006).
Hospitals in Africa occasionally have the reputation of being “unfriendly and
confusing.” The hospital experience can often be intimidating to people from smaller
rural villages. Technology, large medical facilities, and doctors may be completely new

Antiretroviral Therapy 35
to villagers, which can be very daunting. Plus, less time can be spent on hospitality and
patient education since there is a lack of healthcare providers. Therefore, patients may see
doctors and nurses as being impersonal and/or ruthless. Yet, even if they are treated
kindly, some patients may leave confused about their disease and the use of ART.
Whether a patient has personally had negative experiences such as these, or heard about
one from someone else, the hospital setting may deter him from going to the hospital to
receive ART and maintain follow up appointments.
In order to rectify some of the misconceptions, hospitals need to educate their
staff about the potential problems and train them to treat their patients with kindness,
dignity and respect. They should also receive additional training on patient education.
The better patients understand the medical procedures and policies, the more comfortable
they will be in healthcare facilities. Therefore, they will be more likely to return for
follow-up visits and adherence will improve.
An additional factor that affects patient adherence is the long waiting time at the
healthcare facilities. On average, patients will wait for 4 to 6 hours. In Hardon’s study,
some patients had to wait as long as 10-12 hours. This can be very exhausting for
patients, especially for those who traveled long distances to reach the facilities. Some
patients leave without being seen due to discouragement and obligations at home
(Hardon, et al., 2007). A patient in Tanzania commented on this saying, “You may go
there and be kicked like a ball. Maybe you arrive there and you give him/her your referral
slip, you will wait a long time without being attended” (Mshana, et al., 2006). Healthcare
facilities need to address this issue to the best of their abilities. They need to evaluate
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their appointment procedures. If a long waiting time is inevitable, they should warn their
patients of this, and provide food and drinks at a low cost.
Cultural Beliefs
Although most patients will not list cultural beliefs as one of their barriers to
adherence, this is still a possibility in rural villages. Many beliefs regarding health and
disease are passed down through the generations. Often this is not accurate medical
information. Despite patient education in the hospitals or clinics, patients may still hold
to traditional beliefs. This can distort their beliefs regarding the cause of HIV and the best
way to treat it. In fact, 62% of medical providers included in Weiser et al.’s study in
Botswana alleged that treatment adherence was often impeded by traditional etiologic
explanation (Weiser, et al., 2003).
Although Western medical practices are becoming more prevalent in Sub-Saharan
Africa, many rural villages still use their traditional healer. In a study in Botswana, 21%
of HIV patients expected that they would go to a traditional healer for HIV treatment in
the future (Weiser, et al., 2003). Despite the fact that a patient may be receiving ART, he
may consult his or her traditional healer as well. He might even feel pressure from the
community to do so. The traditional healer will often give different recommendations
than trained medical providers. Superstition is often a major component of traditional
healer’s medical practices. Unfortunately, the patient might be advised to stop using
ART, revise the regimen or use a traditional treatment instead. Therefore, this can
become an obstacle to adherence. Patient education and community awareness are key in
this situation.
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Social Stigma
Social stigma may affect patient adherence as well. In fact, in his study, Mshana
suggested that “pervasive stigma remains the most formidable barrier” to distribution of
ART and that it is “the backdrop to all difficulties in achieving a successful ARV
programme” (Mshana, et al., 2006, p. 649, 653). Being HIV positive is viewed as very
dishonorable and is often an immense disgrace on the family. Patients often feel guilty
and ashamed. They may be afraid of disappointing family and friends. It is also possible
that they will be blamed for passing on the virus to a partner, or for being unfaithful to a
spouse (Mshana, et al., 2006). Sometimes employment is denied for these patients. In
addition, these patients will often be abused, neglected, or rejected. (Kohi, Makoae,
Chirwa, Holzemer, Phetlhu, Uys, et al., 2006). For example, in Hardon’s study, some
patients in Botswana were treated badly by their spouse or even abandoned. In Uganda,
some patients were isolated by members of the community (Hardon, et al., 2007). In
addition, one of the participants in Mshana’s study died due to neglect from her family
and food deprivation (Mshana, et al., 2006).
The fear that the social stigma instigates in Africans can often discourage people
from being tested for HIV. Often people will not want to know because they are afraid
that they would be positive for HIV. Instead of being properly tested, some people will
weigh themselves on scales that line the streets. They will watch their weight to see if
they are losing weight. This will give the person an idea if he is HIV positive without
letting anyone else know.
If a person knows that he is HIV positive, he may chose not to receive ART
because of social stigma. In some cases, the person may be concerned about
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confidentiality issues (Weiser, et al., 2003). In other situations, patients may decline ART
because they do not feel they can comply with the treatment program’s regulations. For
instance, in a study in Tanzania, the treatment program being studied required that
patients have a “treatment buddy.” This treatment buddy would remind the patient to take
his medication on a regular basis. Some patients refused treatment because they refused
to disclose their diagnosis to anyone. They were afraid to choose a treatment buddy
because of the social stigma (Mshana, et al., 2006).
Even if patients agree to take ART, they may fear the negative outcomes from
disclosing this information to the extent that they avoid telling anyone. In Weiser, et al.’s
study, 94% of their patients kept their diagnosis of HIV a secret from their community.
Furthermore, 69% of them kept their HIV status a secret from their family. This can
greatly affect adherence to drug regimens (Weiser, et al., 2003).
Since many patients do not disclose this information to anyone, it means that they
will have to take their medication in secret. It can be difficult to find a time and place to
be alone; therefore, it leads to inconsistency in taking their medication. In addition, these
patients will not receive support and encouragement from their family to take their
medication. If the patient’s family knows about their HIV status, there is a chance that
they will be proactive and help them find transportation to the clinic or hospital and
remind them to take their medication. However, due to the social stigma, some families
will provide little to no support concerning their therapy; they may even ostracize them
(Hardon, et al., 2007). In some cases, when children have HIV, the family may send them
to school without their medications because they want to hide the fact that their child has
HIV. This would also lead to poor adherence (Chesney, 2000).

Antiretroviral Therapy 39
Adherence is also affected by disclosure (or nondisclosure) of HIV status to
patients’ employers. Patients take a risk when disclosing this information at their
workplace. Some patients may lose their job or face other kinds of discrimination if their
employers finds out. Each patient has to decide whether or not to tell his employer that he
is HIV positive. If the employer does not know, the patient may not be able to get time
off of work to go to the clinic or hospital for his follow-up visits and ART refills.
However, if the patient tells his employer, he may lose his job, or the employer may not
support his need for treatment and care. Therefore, the patient may not be able to adhere
to his drug regimen because he cannot get time off to go to a healthcare facility (Hardon,
et al., 2007). Social stigma needs to be targeted in a similar way to that of cultural
issues—through education. First, healthcare providers need to assess the affects of social
stigma in their communities. A possible assessment tool to use is provided in Appendix B
(Hozemer, Uys, Chirwa, Greeff, Makoae, Kohi, et al., 2007). Then whole communities
need to be taught about HIV/AIDS and the importance of treatment. It is also important
for the community’s leaders and influential people advocate for HIV testing and
treatment.
Poor Quality Counseling
In order for patients to be able to adhere well to their ART drug regimen, they
need to receive counseling and education. Without it, patients may not comprehend the
importance of taking medication. Patients with insufficient counseling and education will
be much less likely to continue taking their medication when they encounter side-effects
and other barriers. They will also be more likely to quit taking the medication when they
begin to feel well. In addition, they may not understand the drug regimen itself. For
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instance, they may take their medication too often or too seldom. This results in poor
adherence, increased vial load, and a higher risk of drug resistance. Many healthcare
workers in clinics and hospitals of Sub-Saharan Africa do not have proper training in
counseling. In a study that reviewed exit interviews, only 21% of patients on ART
received counseling (Hardon, et al., 2007). Therefore, this is a major need in these
healthcare facilities.
Stenson, et al. devised a tool to assess patients’ need for counseling during their
study in South Africa. Healthcare providers should use something similar to this tool
routinely during their ART visits. This tool is included in Appendix C (Stenson,
Charalambous, Dwadwa, Pemba, Du Toit, Baggaley, et al., 2005). HIV patients need to
be taught about HIV itself, when to take the pill, how often to take the pill, and side
effects of the medication. This helps the patient understand the situation and become
more organized. They should also be counseled about the importance of adhering to the
regimen, how to talk to family and friends about it, how to deal with the social stigma,
and any other concerns that the patient may have. It may also be helpful to tailor the drug
regimen to suit the patient’s life. One way to do this is to link particular daily activities
with taking their medication (Chesney, 2000).
Resistance to Drugs
Despite the fact that antiretroviral therapy has been improving the lives of
millions of HIV patients, a high concern for these patients is that they might become
resistant to the medications. Drug resistance can become a major problem when patients
do not adhere to their drug regimen. A study conducted by Laurent determined that
approximately 12.5% of patients became resistant to at least one drug (Akileswaran,
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Lurie, Flanigan, & Mayer, 2005). This problem is significant because when resistance
develops, the patient has to be switched to a different drug regimen—second line
treatments. This often costs about 10 times as much as the first line treatment (Hardon, et
al., 2007). This makes it hard for the healthcare facilities in Sub-Saharan Africa to access
and provide the necessary drugs.
To address this concern, a program called the Global HIV Drug Surveillance
Network is currently being developed to monitor global resistance and provide strategies
to minimize resistance. The World Health Organization is collaborating with the
International AIDS Society for this program (WHO, 2006). Research on resistance in
sub-Saharan Africa is limited. However, data collected thus far has paralleled data from
more developed countries such as the U.S. Multiple drug resistance has increased from
1.1% of patients to 13.2% of patients in the United States between 1999 and 2001 (Vella
& Palmisano, 2005). In order to prevent future cases of resistance, it is important to
understand how resistance develops, determine which classes of ART patients most likely
to become resistant to, and track and prevent resistance.
There are multiple reasons why resistance develops. First of all, HIV has a very
high turnover rate. In a chronic infection, half of the virons in the body are lost every 6
hours. In order to make up for this loss, between 1 and 10 billion virons are produced on
a daily basis. Secondly, there is a high likelihood of mutation. It is estimated that 10
incorrect base pairs are incorporated into viral DNA every replication (Lehne, 2007).
The high probability of error is due to the fact that HIV reverse transcriptase does not
have a proofreading mechanism. Once a viron has mutated, it is harder for a drug to stop
its replication. For instance, mutation can lead to a structural change in gp41 (the
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glycoprotein on HIV’s envelope). This can prevent a fusion inhibitor from binding to it,
making the drug ineffective. Or if a mutation causes HIV reverse transcriptase to change
shape, the administration of NRTIs and NNRITs will be useless. As a result of varying
mutations, many genetically different strains of HIV can be found within the same patient
(Vella & Palmisano, 2005 & Lehne, 2007).
If a patient has never been on antiretroviral therapy, drug-sensitive virons will
greatly outnumber resistant virons. This is because the replication of “normal” virons is
unopposed. Once ART is initiated, the drug prevents numerous viruses from replicating;
the only surviving viruses are the less susceptible (or resistant) strains. These are the only
ones that are able to continue replicating. This is similar to the idea of the “survival of the
fittest.” Therefore, when a patient begins treatment, it is possible for him or her to quickly
become drug-resistant. If resistance occurs, there is typically cross resistance with drugs
within the same class (Vella & Palmisano, 2005).
Two other major causes of resistance include poor patient adherence or a drug
regimen with too low of a potency. These problems make it impossible to suppress the
virus and allow the virus to replicate itself (Lehne, 2007). It is also important to note that
HIV-2 (found in West Africa) is more resistant to medications. Therefore, treatment
might be more difficult (Mullins, et al., 2004).
The reason that physicians prescribe multiple medications for HIV is to prevent
resistance. It is rare that a mutation in HIV could cause resistance to three or four
different drugs at the same it. Each drug has a different target area which would require a
mutation in order for the HIV strain to become drug resistant. One the other hand, it
would be very easy for a patient to become resistant to a single drug used alone (Lehne,
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2007).
Once resistance itself is understood, statistics regarding resistance to specific
drugs need to be analyzed. Concerning individual classes of antiretroviral therapy,
research shows that patients are most likely to develop resistance to NRTIs. The CATCH
study in Europe compared resistance to each class of drug in treatment-naive patients
(those who had never received ART beforehand). There results were as follows: NRTIs6.9% of patients, NNRTIs: 2.6%, protease inhibitors: 2.2%, and using a combination of at
least two classes: 1.7% of patients (Vella & Palmisano, 2005). This showed which drugs
patients are most likely to become resistant. In addition, it confirmed the idea that using a
combination of drugs decreases the risk of resistance. Data collected by Laurent in Africa
suggested the same order of resistance when comparing classes of drugs (Akileswaran et
al., 2005).
Next, steps need to be taken to prevent drug resistance. Currently, most healthcare
facilities in Sub-Saharan Africa do not have the resources and equipment necessary to
test for resistance. Developing cheaper methods of testing for HIV resistance would be
beneficial. In addition, there are a variety of other methods of preventing resistance that
should be implemented. First of all, global research about the epidemic needs to be
increased. As this information becomes organized, worldwide surveillance programs
need to be in place so that the epidemic and treatment can be tracked. Secondly, patients
need to be encouraged to adhere to their regimen—especially when on resistant-prone
classes of drugs. Furthermore, it is important for patients to discontinue their ineffective
drugs. Thirdly, since beginning drug therapy increases the risk of resistance, it is
important to weigh the pros and cons on an individual basis before beginning a patient on
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a particular regimen. Lastly, education about HIV and transmission should be continued.
This is important because once a patient is drug-resistant, these are the strains of HIV that
he or she can transmit to another person (Vella & Palmisano, 2005).
A main factor that reduces a patient’s chance of becoming resistance is
maintaining optimal patient adherence. Possible suggestions were listed above and
included ideas such as additional fundraising for patient expenses and providing
transportation to healthcare facilities. In addition, patients should be provided with
supplemental food, monitored for severe side-effects and be switched to a different
regimen if needed. Finally, education of patients, providers and communities are
necessities. Even though these suggestions will not eliminate all obstacles, they will make
distribution and maintenance of ART regimens more feasible.
Despite the multitude of possible obstacles, the use of ART in Sub-Saharan Africa
is well worth the risk. Even though a complete cure may not be possible, putting more
patients on ART will improve quality of life and increase life expectancy. Access to HIV
can be improved by determining where the unmet need is and targeting the obstacles of
providing treatment. Taking a proactive stance to do this will help to fight the devastating
HIV epidemic that has been sweeping the globe.
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Appendix A
Antiretroviral Therapy Survey
Please answer the following questions and return to Elizabeth Paquette at
ejpaquette@liberty.edu.
Thank you!

(Press Tab key to advance to next data entry field)

1) What is your name/title?
2) What country/city do you serve in?
3) What is the name of your medical facility?
4) Are you able to provide antiretroviral therapy for HIV/AIDS patients?
yes
no
If no, why not?
If yes, continue please continue to answer questions 5-14.
5) Approximately how many HIV/AIDS patients do you provide antiretroviral
therapy for each year?
6) Approximately what percent of HIV patients seeking treatment are you able to
help?
7) Who provides the funding for your facility?
Government
NGO
SIM Projects
Private grants
Other (please specify)
8) Are you able to provide antiretroviral therapy free of charge?
If not, what is the approximate cost for each patient?

yes

no

9) Which classes of drugs are available to you? (check all that apply)
NRTIs
NNRTIs
Protease Inhibitors
Fusion Inhibitors
10) Which drug regimen do you use most frequently?
11) Does your facility have the capability of testing for resistance to drugs?
no

yes
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If not, please skip to question 14.
12) Approximately what percent of the patients in your facility have become resistant
to 1 or more drug?
13) Which is the most common class of drug that your patients have become resistant
to?
NRTIs
NNRTIs
Protease Inhibitors
Fusion Inhibitors
14) What major regulations does the government place on you in providing
antiretroviral therapy?

15) Have you seen social stigma effect adherence to drug regimens?
no
If so, in what ways?

yes

16) What major obstacles have you encountered while trying to provide treatment?
(check all that apply)
Lack of funds
Lack of staff
Lack of facility
Antiretroviral drug availability
Government regulations
Geographic proximity to treatment facility
Patient adherence to drug regimen
Resistance to drugs
Social stigma and cultural issues
Other (please specify)
Comments:
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Appendix B
HIV/AIDS and Stigma Tool
I’m going to read a list of events that may have happened to you during the past three months. After I read
each item, please tell me how often it happened to you because of your HIV status:
In the past 3 months, how often did the following events happen because of your HIV status?
Never
Once
Several
Most of
or twice times
the time
1. I was told to use my own eating utensils.
2. I was asked not to touch someone’s child.
3. I was made to drink last from the cup.
4. Someone mocked me when I passed by.
5. I stopped eating with other people.
6. I was asked to leave because I was coughing.
7. Someone stopped being my friend.
8. A friend would not chat with me.
9. I was called bad names.
10. People sang offensive songs when I passed by.
11. I was told that I have no future.
12. Someone scolded me.
13. I was told that God is punishing me.
14. I was made to eat alone.
15. Someone insulted me.
16. People avoided me
17. People cut down visiting me
18. People ended their relationships with me
19. I was blamed for my HIV status
20. Someone tried to get me fired from my job.
21. My employer denied me opportunities.

The next set of questions is about your experiences in the hospital or clinic. In the past 3 months, how often
did the following events happen because of your HIV status?
Never
22. I was denied health care.
23. I was refused treatment because I was told I was going
to die anyway.
24. I was discharged from the hospital while still needing care.

Once
or twice

Several
times

Most of
the time
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25. I was shuttled around instead of being helped by a nurse.
26. At the hospital/clinic, I was made to wait until last
27. At the hospital, I was left in a soiled bed.
28. In the hospital or clinic, my pain was ignored.

These questions are about some of your thoughts or feelings. How often have you thought or felt this way
during the past 3 months because of your HIV status?
Never
29. I felt that I did not deserve to live.
30. I felt ashamed of having this disease.

(Hozemer, Uys, Chirwa, Greeff, Makoae, Kohi, et al., 2007)

Once
or twice

Several
times

Most of
the time
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Appendix C
Counseling Resource
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(Stenson, Charalambous, Dwadwa, Pemba, Du Toit, Baggaley, et al., 2005)

